Peptides as drug delivery vehicles across biological barriers

被引：74
作者：
Ghosh D. [1 ]
Peng X. [1 ]
Leal J. [1 ]
Mohanty R.P. [1 ]
机构：
[1] Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Ave, Austin, 78712, TX
来源：
Journal of Pharmaceutical Investigation | 2018年 / 48卷 / 1期
关键词：
Blood–brain barrier; Carrier; Drug delivery; GI; Peptides; Tumor;
D O I：
10.1007/s40005-017-0374-0
中图分类号：
学科分类号：
摘要：
Peptides are small biological molecules that are attractive in drug delivery and materials engineering for applications including therapeutics, molecular building blocks and cell-targeting ligands. Peptides are small but can possess complexity and functionality as larger proteins. Due to their intrinsic properties, peptides are able to overcome the physiological and transport barriers presented by diseases. In this review, we discuss the progress of identifying and using peptides to shuttle across biological barriers and facilitate transport of drugs and drug delivery systems for improved therapy. Here, the focus of this review is on rationally designed, phage display peptides, and even endogenous peptides as carriers to penetrate biological barriers, specifically the blood–brain barrier (BBB), the gastrointestinal tract (GI), and the solid tumor microenvironment (T). We will discuss recent advances of peptides as drug carriers in these biological environments. From these findings, challenges and potential opportunities to iterate and improve peptide-based approaches will be discussed to translate their promise towards the clinic to deliver drugs for therapeutic efficacy. © 2017, The Korean Society of Pharmaceutical Sciences and Technology.
引用
收藏
页码：89 / 111
页数：22
相关论文
共 185 条
[71]  
Laakkonen P., Porkka K., Hoffman J.A., Ruoslahti E., A tumor-homing peptide with a targeting specificity related to lymphatic vessels, Nat Med, 8, pp. 751-755, (2002)
[72]  
Langguth P., Bohner V., Heizmann J., Et al., The challenge of proteolytic enzymes in intestinal peptide delivery, J Control Release, 46, pp. 39-57, (1997)
[73]  
Larhed A.W., Artursson P., Grasjo J., Bjork E., Diffusion of drugs in native and purified gastrointestinal mucus, J Pharm Sci, 86, pp. 660-665, (1997)
[74]  
Larhed A.W., Artursson P., Bjork E., The influence of intestinal mucus components on the diffusion of drugs, Pharm Res, 15, pp. 66-71, (1998)
[75]  
Lee V.H.L., Yamamoto A., Penetration and enzymatic barriers to peptide and protein absorption, Adv Drug Deliv Rev, 4, pp. 171-207, (1989)
[76]  
Lee J.H., Engler J.A., Collawn J.F., Moore B.A., Receptor mediated uptake of peptides that bind the human transferrin receptor, Eur J Biochem, 268, pp. 2004-2012, (2001)
[77]  
Li J., Feng L., Fan L., Et al., Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides, Biomaterials, 32, pp. 4943-4950, (2011)
[78]  
Li J., Zhang Q., Pang Z., Et al., Identification of peptide sequences that target to the brain using in vivo phage display, Amino Acids, 42, pp. 2373-2381, (2012)
[79]  
Li J., Zhang C., Li J., Et al., Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides, Pharm Res, 30, pp. 1813-1823, (2013)
[80]  
Li M., Tang Z., Zhang D., Et al., Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models, Biomaterials, 51, pp. 161-172, (2015)
3456789101112